Theradaptive Funding: How Much Did They Raise & Key Investors

How Much Did Theradaptive Raise?
Funding & Key Investors

Theradaptive has secured a significant enterprise-level funding round, with recent capital injection amounting to $26M. This latest strategic investment follows a substantial prior funding history, bringing the company's total financing to $32.2M. The company is currently in a growth phase, indicated by its major enterprise-level funding context.

What is Theradaptive?

Theradaptive

Manufacturing

Pharmaceuticals

Business Services

Theradaptive is a venture-backed biopharmaceutical company focused on developing a therapeutic delivery platform technology designed for targeted tissue regeneration. The company's innovative approach aims to revolutionize treatment delivery for various regenerative medicine applications.

How much funding has Theradaptive raised?

Theradaptive has raised a total of $32.2M across 2 funding rounds:

2021

Series A

$6.2M

2023

Series A

$26M

Series A (2021): $6.2M with participation from AMP Squared

Series A (2023): $26M, investors not publicly disclosed

Key Investors in Theradaptive

AMP Squared

AMP Squared is an investor participating in the funding round, with a focus that is not explicitly detailed.

What's next for Theradaptive?

With this major strategic investment, Theradaptive is poised to accelerate the development and commercialization of its proprietary therapeutic delivery platform. The substantial capital infusion will likely fuel further research and development, clinical trials, and potential market expansion, solidifying its position in the biopharmaceutical landscape. Future growth will depend on successful clinical outcomes and strategic partnerships.

See full Theradaptive company page

See More Financial Insights